New inhibitors of poly(ADP-ribose) polymerase (PARP)

Bibliography

• ELIASSON MJ, SAMPEI K, MANDIR AS et al.: Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med. (1997) 3:1089–1095.
   PubMed Web of Science ®Google Scholar
• AFFAR EB, SHAH RG, POIRIER GG: Poly(ADP-ribose) turnover in quail myoblast cells: relation between the polymer level and its catabolism by glycohydrolase. Mol. Cell Biochem. (1999) 193:127–135.
   PubMed Web of Science ®Google Scholar
• MIWA M, TANAKA M, MATSUSHIMA T, SUGIMURA T: Purification and properties of glycohydrolase from calf thymus splitting ribose-ribose linkages of poly(adenosine diphosphate ribose)../. Biol. Chem. (1974) 249:3475–3482.
   PubMed Web of Science ®Google Scholar
• SMITH S: The world according to PARP. Trends Biochem. Sci. (2001) 26:174–179.
   PubMed Web of Science ®Google Scholar
• •Excellent and brief review of the molecular, biological and cellular function of the PARP family members.
   Google Scholar
• MA Q, BALDWIN KT, RENZELLI AJ, MCDANIEL A, DONG L: TCDD-inducible poly(ADP-ribose) polymerase: a novel response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Biophys. Res. Commun. (2001) 289:499–506.
   PubMed Web of Science ®Google Scholar
• CHAMBON P, WEILL JD, MANDEL P: Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. (1963) 11:39–43.
   PubMed Web of Science ®Google Scholar
• AME JC, ROLLI V, SCHREIBER V et al: PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. 'Bk./. Chem. (1999) 274:17860–17868.
   PubMed Web of Science ®Google Scholar
• SALLMANN FR, VODENICHAROV MD, WANG ZQ, POIRIER GG: Characterization of sPARP-1. An alternative product of PARP-1 gene with poly(ADP-ribose) polymerase activity independent of DNA strand breaks. J.Biol. Chem. (2000) 275:15504–15511.
   Google Scholar
• KRUPITZA G, CERUTTI P: Poly (ADP-ribosylation) of histones in intact human keratinocytes. Biochemistry (1989) 28:4054–4060.
   PubMed Web of Science ®Google Scholar
• KUMARI SR, MENDOZA-ALVAREZ H, ALVAREZ-GONZALEZ R: Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment. Cancer Res. (1998) 58:5075–5078.
   PubMed Web of Science ®Google Scholar
• YOSHIHARA K, ITAYA A, TANAKA Y et al.: Inhibition of DNA polymerase a, DNA polymerase 13, terminal deoxynucleotidyl transferase, and DNA ligase II by poly(ADP-ribosyl)ation reaction in vitro. Biochem. I3iophys. Res. Commun. (1985) 128:61–67.
   Google Scholar
• DARBY MK, SCHMITT B, JONGSTRA -BILEN J, VOSBERG HP: Inhibition of calf thymus Type II DNA topoisomerase by poly(ADP-ribosylation). EMBO J. (1985) 4:2129–2134.
   PubMed Web of Science ®Google Scholar
• MASSON M, NIEDERGANG C, SCHREIBER V, MULLER S, MENISSIER-DE MURCIA J, DE MURCIA G: XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell Biol. (1998) 18:3563–3571.
   PubMed Web of Science ®Google Scholar
• MENISSIER DM, RICOUL M, TARTIER L et al: Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. (2003) 22:2255–2263.
   PubMed Web of Science ®Google Scholar
• SHALL S, DE MURCIA G: Poly (ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res. (2000) 460:1-15.
   Google Scholar
• SIMBULAN-ROSENTHAL CM, ROSENTHAL DS, LUO R, LI JH, ZHANG J, SMULSON ME: Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy. Nucleic Acids Res. (2001) 29:841–849.
   PubMed Web of Science ®Google Scholar
• BURKLE A, HEILBRONN R, ZUR HH: Potentiation of carcinogen-induced methotrexate resistance and dihydrofolate reductase gene amplification by inhibitors of poly(adenosine diphosphate-ribose) polymerase. Cancer Res. (1990) 50:5756–5760.
   PubMed Web of Science ®Google Scholar
• WALDMAN AS, WALDMAN BC: Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation). Nucleic Acids Res. (1991) 19:5943–5947.
   PubMed Web of Science ®Google Scholar
• AUGUSTIN A, SPENLEHAUER C, DUMOND H et al.: PARP-3 localizes preferentially to the daughter centriole and interferes with the Gl/S cell cycle progression. J. Cell Sci. (2003) 116:1551–1562.
   PubMed Web of Science ®Google Scholar
• JOHANSSON M: A human poly (ADP-ribose) polymerase gene family (ADPRTL): cDNA cloning of two novel poly(ADP-ribose) polymerase homologues. Genomics (1999) 57:442–445.
   PubMed Web of Science ®Google Scholar
• KANAI M, UCHIDA M, HANAI S, UEMATSU N, UCHIDA K, MIWA M: Poly(ADP-ribose) polymerase localizes to the centrosomes and chromosomes. Biochem. Biophys. Res. Commun. (2000) 278:385–389.
   PubMed Web of Science ®Google Scholar
• KANAI M, TONG WM, SUGIHARA E, WANG ZQ, FUKASAWA K, MIWA M: Involvement of poly(ADP-Ribose) polymerase 1 and poly(ADP-Ribosyl)ation in regulation of centrosome function. Mol. Cell Biol. (2003) 23:2451–2462.
   PubMed Web of Science ®Google Scholar
• KAMINKER PG, KIM SH, TAYLOR RD et al.: TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression. Biol. Chem. (2001) 276:35891–35899.
   Web of Science ®Google Scholar
• SMITH S, GIRIAT I, SCHMITT A, DE LANGE T: Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science (1998) 282:1484–1487.
   PubMed Web of Science ®Google Scholar
• SMITH S, DE LANGE T: Tankyrase promotes telomere elongation in human cells. Curc Biol. (2000) 10:1299–1302.
   PubMed Web of Science ®Google Scholar
• DYNEK JN, SMITH S: Resolution of sister telomere association is required for progression through mitosis. Science (2004) 304:97–100.
   PubMed Web of Science ®Google Scholar
• COOK BD, DYNEK JN, CHANG W, SHOSTAK G, SMITH S: Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol. Cell Biol. (2002) 22:332–342.
   PubMed Web of Science ®Google Scholar
• CHI NW, LODISH HF: Tankyrase is a golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles. J. Biol. Chem. (2000) 275:38437–38444.
   PubMed Web of Science ®Google Scholar
• SMITH S, DE LANGE T: Cell cycle dependent localization of the telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes. J. Cell Sci. (1999) 112 (21):3649–3656.
   PubMed Web of Science ®Google Scholar
• KICKHOEFER VA, SIVA AC, KEDERSHA NL et al: The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J. Cell Biol. (1999) 146:917–928.
   PubMed Web of Science ®Google Scholar
• KICKHOEFER VA, RAJAVEL KS, SCHEFFER GL, DALTON WS, SCHEPER RJ, ROME LH: Vaults are up-regulated in multidrug-resistant cancer cell lines. .1 Biol. Chem. (1998) 273:8971–8974.
   PubMed Web of Science ®Google Scholar
• SCHROEIJERS AB, SIVA AC, SCHEFFER GL et al: The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines. Cancer Res. (2000) 60:1104–1110.
   PubMed Web of Science ®Google Scholar
• MOSSINK MH, VAN ZON A, FRANZEL -LUITEN E et al.: Disruption of the murine major vault protein (IVIVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res. (2002) 62:7298–7304.
   Google Scholar
• MOSSINK MH, DE GROOT J, VAN ZON A et al: Unimpaired dendritic cell functions in MVP/LRP knockout mice. Immunology (2003) 110:58–65.
   PubMed Web of Science ®Google Scholar
• MA Q: Induction and superinduction of2,3,7,8-tetrachlorodibenzo-rho-dioxin-inducible poly(ADP-ribose) polymerase: role of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator transcription activation domains and a labile transcription repressor. Arch. Biochem. Biophys. (2002) 404:309–316.
   PubMed Web of Science ®Google Scholar
• MATSUO R, MURAYAMA A, SAITOH Y, SAKAKI Y, INOKUCHI K: Identification and cataloging of genes induced by long-lasting long-term potentiation in awake rats. J. Neurochem. (2000) 74:2239–2249.
   PubMed Web of Science ®Google Scholar
• KURT RA, BERNSTEIN RM, SCHLUTER SF, PARK J, MARCHALONIS JJ, AKPORIAYE E: The isolation and identification of genes differentially expressed in progressing versus regressing tumours through subtractive hybridization. (1996) GenBank acc. no.: U55178.
   Google Scholar
• CHIARUGI A, MOSKOWITZ MA: Cell biology. PARP-1 - a perpetrator of apoptotic cell death? Science (2002) 297:200–201.
   Google Scholar
• YU SW, WANG H, POITRAS MF et al:Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 297:259–263.
   PubMed Web of Science ®Google Scholar
• COSI C: New inhibitors of poly(ADP-ribose) polymerase and their potential therapeutic targets. Expert Opin. Ther. Patents (2002) 12:1047–1071.
   Web of Science ®Google Scholar
• SZABO C, DAWSON VL: Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol. Sci. (1998) 19:287–298.
   PubMed Web of Science ®Google Scholar
• TENTORI L, PORTARENA I, GRAZIANI G: Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol. Res. (2002) 45:73–85.
   PubMed Web of Science ®Google Scholar
• VIRAG L, SZABO C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev (2002) 54:375–429.
   PubMed Web of Science ®Google Scholar
• •Excellent review summarising the potential therapeutic utility and possible mechanisms of action of PARP inhibitors.
   Google Scholar
• PIEPER AA, VERMA A, ZHANG J, SNYDER SH: Poly(ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol. Sci. (1999) 20:171–181.
   PubMed Web of Science ®Google Scholar
• CHIARUGI A: Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol. Sci. (2002) 23:122–129.
   PubMed Web of Science ®Google Scholar
• HONG SJ, DAWSON TM, DAWSON VL: Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. (2004) 25:259–264.
   PubMed Web of Science ®Google Scholar
• BERGER NA: Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res. (1985) 101:4–15.
   PubMed Web of Science ®Google Scholar
• HA HC, SNYDER SH: Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc. Natl. Acad. Li. USA (1999) 96:13978–13982.
   PubMed Web of Science ®Google Scholar
• FERRARIS D, FICCO RP, DAIN D et al.: Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries. Bioorg. Med. Chem. (2003) 11:3695–3707.
   Google Scholar
• FERRARIS D, KO YS, PAHUTSKI T et al.: Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[K-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries. J. Med. Chem. (2003) 46:3138–3151.
   Google Scholar
• •Detailed SAR study of aza -phenanthridinones as neuro- and cardloprotectlye agents and in vivo animal data in stroke and heart ischaemia.
   Google Scholar
• KHAN TA, RUEL M, BIANCHI C et al: Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. Am . Coll. Surg. (2003) 197:270–277.
   PubMed Web of Science ®Google Scholar
• KOMJATI K, MABLEY JG, VIRAG L, SOUTHAN GJ, SALZMAN AL, SZABO C: Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int. J. Mol. Med. (2004) 13:373–382.
   PubMed Web of Science ®Google Scholar
• SHIEH WM, AME JC, WILSON MV et al: Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. I Biol. Chem. (1998) 273:30069–30072.
   Web of Science ®Google Scholar
• AME JC, ROLLI V, SCHREIBER V et al.: PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J. Biol. Chem. (1999) 274:17860–17868.
   PubMed Web of Science ®Google Scholar
• SCHREIBER V, AME JC, DOLLE P et al.: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRC Cl. I Biol. Chem. (2002) 277:23028–23036.
   Web of Science ®Google Scholar
• PASCHEN W, OLAH L, MIES G: Effect of transient focal ischemia of mouse brain on energy state and NAD levels: no evidence that NAD depletion plays a major role in secondary disturbances of energy metabolism. Neurochem . (2000) 75:1675–1680.
   PubMed Web of Science ®Google Scholar
• LE PAGE C, SANCEAU J, DRAPIER JC, WIETZERBIN J: Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF-KB activation. Biochem. Biophys. Res. Commun. (1998) 243:451–457.
   PubMed Web of Science ®Google Scholar
• OLIVER FJ, MENISSIER-DE MURCIA J, NACCI C et al: Resistance to endotoxic shock as a consequence of defective NF-KB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO (1999) 18: 4446–4454.
   PubMed Web of Science ®Google Scholar
• SANCAR A, LINDSEY-BOLTZ LA, UNSAL-KACCMAZ K, LINN S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Ann. Rev Biochem. (2004) 73:39–85.
   PubMed Web of Science ®Google Scholar
• SUAREZ-PINZON WL, MABLEY JG, POWER R, SZABO C, RABINOVITCH A: Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes (2003) 52:1683–1688.
   PubMed Web of Science ®Google Scholar
• SORIANO FG, PACHER P, MABLEY J, LIAUDET L, SZABO C: Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ. Res. (2001) 89:684–691.
   PubMed Web of Science ®Google Scholar
• SORIANO FG, VIRAG L, JAGTAP P et al.: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med. (2001) 7:108–113.
   PubMed Web of Science ®Google Scholar
• MURAKAMI K, ENKHBAATAR P, SHIMODA K et al: Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock (2004) 21:126–133.
   PubMed Web of Science ®Google Scholar
• CHIARUGI A: Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br. Pharmacol (2002) 137:761–770.
   PubMed Web of Science ®Google Scholar
• VIRAG L, BAT P, BAK I et al: Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma. Med. Sri. Monit. (2004) 10:BR77-BR83.
   Google Scholar
• LIAUDET L, PACHER P, MABLEY JGet al.: Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am. J. Respir. nit. Care Med. (2002) 165:372–377.
   Google Scholar
• VERES B, RADNAI B, GALLYAS F JR.et al.: Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J. Pharmacol Exp. Ther. (2004) 310:247–255.
   Google Scholar
• VERES B, GALLYAS F JR, VARBIRO G et al.: Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase-1 inhibitor in endotoxin-induced septic shock. Biochem. Pharmacol (2003) 65:1373–1382.
   PubMed Web of Science ®Google Scholar
• CALABRESE CR, ALMASSY R, BARTON S et al.: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. (2004) 96:56–67.
   PubMed Web of Science ®Google Scholar
• •Detailed study of the in vivo activity of a highly potent PARP inhibitor in anti-cancer chemo- and radiosensitisation.
   Google Scholar
• SUH SW, AOYAMA K, CHEN Y et al: Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. J. Neurosci. (2003) 23:10681–10690.
   PubMed Web of Science ®Google Scholar
• MIKNYOCZKI SJ, JONES-BOLIN S, PRITCHARD S et al: Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mot. Cancer Ther. (2003) 2:371–382.
   PubMed Web of Science ®Google Scholar
• TENTORI L, LEONETTI C, SCARSELLA M et al: Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood (2002) 99:2241–2244.
   PubMed Web of Science ®Google Scholar
• RUF A, MENNISSIER DM, DE MURCIA G, SCHULZ GE: Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl. Acad. Sri. USA (1996) 93:7481–7485.
   PubMed Web of Science ®Google Scholar
• RUF A, DE MURCIA G, SCHULZ GE: Inhibitor and NAD' binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry (1998) 37:3893–3900.
   PubMed Web of Science ®Google Scholar
• OLIVER AW, AME JC, ROE SM, GOOD V, DE MURCIA G, PEARL LH: Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucleic Acids Res. (2004) 32:456–464.
   PubMed Web of Science ®Google Scholar
• •First crystal structure of the catalytic fragment of PARP-2 in comparison to the catalytic site of PARP–1.
   Google Scholar
• KINOSHITA T, NAKANISHI I, WARIZAYA M et al.: Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett. (2004) 556:43–46.
   PubMed Web of Science ®Google Scholar
• PERKINS E, SUN D, NGUYEN A et al: Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res. (2001) 61 4175–4183.
   PubMed Web of Science ®Google Scholar
• KERRIGAN F, COCKCROFT X, DILLON.K.J. et al: Imide-substituted 4-benzy1-2H-phthalazin-1-ones: potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). 12th RSC-SCI Medicinal Chemistry Symposium. Cambridge, UK (2003).
   Google Scholar
• BANASIK M, UEDA K: Inhibitors and activators of ADP-ribosylation reactions. Mot. Cell Biochem. (1994) 138: 185–197.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of early PARP Inhibitors with inhibitory activity given from various comparative references.
   Google Scholar
• LI JH, ZHANG J: PARP inhibitors. 'Drugs (2001) 4:804–812.
   PubMedGoogle Scholar
• SOUTHAN GJ, SZABO C: Poly(ADP-ribose) polymerase inhibitors. Curr. Med. Chem. (2003) 10:321–340.
   PubMed Web of Science ®Google Scholar
• CANAN KOCH SS, THORESEN LH, TIKHE JG et al.: Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J. Med. Chem. (2002) 45:4961–4974.
   PubMed Web of Science ®Google Scholar
• LI H, GOLDSTEIN BM: Carboxamide group conformation in the nicotinamide and thiazole-4-carboxamide rings: implications for enzyme binding.' Med. Chem. (1992) 35:3560–3567.
   Web of Science ®Google Scholar
• SUTO MJ, TURNER WR, ARUNDEL -SUTO CM, WERBEL LM, SEBOLT-LEOPOLD JS: Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des. (1991) 6:107–117.
   PubMedGoogle Scholar
• BANASIK M, KOMURA H, SHIMOYAMA M, UEDA K: Specific inhibitors of poly(ADP-ribose) synthetase and mono (ADP-ribosyl)transferase. Biol . Chem. (1992) 267:1569–1575.
   Web of Science ®Google Scholar
• GRIFFIN RJ, SRINIVASAN S, BOWMAN K et al: Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J. Med. Chem. (1998) 41:5247–5256.
   Google Scholar
• SHINKWIN AE, WHISH WJ, THREADGILL MD: Synthesis of thiophenecarboxamides, thieno [3,4-c[pyridin-4 (5H) -ones and thieno [3, 4 - cll pyrimidin-4 (3H) -ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). Bioorg. Med. Chem. (1999) 7:297–308.
   PubMed Web of Science ®Google Scholar
• BOWMAN KJ, WHITE A, GOLDING BT, GRIFFIN RJ, CURTIN NJ: Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br. J. Cancer (1998) 78:1269–1277.
   PubMed Web of Science ®Google Scholar
• WHITE AW, ALMASSY R, CALVERT AH et al: Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J. Med. Chem. (2000) 43:4084–4097.
   Google Scholar
• ABDELKARIM GE, GERTZ K, HARMS C et al: Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int. Mol Med. (2001) 7:255–260.
   PubMed Web of Science ®Google Scholar
• IWASHITA A, YAMAZAKI S, MIHARA K et al: Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2- [3- [4- (4-chloropheny9-1-piperaziny1] propy11-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine model of Parkinson's disease. J Pharmacol Exp. Ther. (2004) 309:1067–1078.
   PubMed Web of Science ®Google Scholar
• IWASHITA A, TOJO N, MATSUURA S et al.: A novel and potent PARP-1 inhibitor, 5-chloro 2 [3 (4 pheny1-3, 6-dihydro-1 (2F1)-pyridinyl)propyll -4 (3H) - quinazolinone (FR247304), attenuates neuronal damage in vitro and in vivo models of cerebral ischemia. Pharmacol Exp. Ther. (2004) 310:425–436.
   PubMed Web of Science ®Google Scholar
• STEINHAGEN H, GERISCH M, MITTENDORF J, SCHLEMMER KH, ALBRECHT B: Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett. (2002) 12:3187–3190.
   PubMed Web of Science ®Google Scholar
• SHIGA F, TAKANO Y, KANDA T et al:Synthesis of novel isoquinolinone derivatives as highly potent PARP inhibitors. 227th National meeting of the American Chemical Society Anaheim, CA USA. MEDI-288 (2004).
   Google Scholar
• WHITE AW, CURTIN NJ, EASTMAN BW et al.: Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:2433–2437.
   PubMed Web of Science ®Google Scholar
• PELLICIARI R, CAMAIONI E, CONSTANTINO G et al.: Towards new neuroprotective agents: design and synthesis 4H-thienoisoquinolin-5-one derivatives as potent PARP-1 inhibitors. II Farmaco (2003) 58:851–858.
   PubMedGoogle Scholar
• MURAKAMI K, ENKHBAATAR P, SHIMODA K et al: Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock (2004) 21:126–133.
   PubMed Web of Science ®Google Scholar
• BROCK WA, MILAS L, BERGH S, LO R, SZABO C, MASON KA: Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. (2004) 205:155–160.
   PubMed Web of Science ®Google Scholar
• MUSICK KY, WEINTRAUB PM, EASTWOOD P et al: Design, synthesis and SAR evaluation of novel inhibitors of poly(ADP-ribose)polymerase (PARP). 226th National meeting of the American Chemical Society New York, NY MEDI-121. (2003).
   Google Scholar
• JAGTAP PG, SOUTHAN GJ, BALOGLU E et al: The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett. (2004) 14:81–85.
   PubMed Web of Science ®Google Scholar
• CHIARUGI A, MELI E, CALVANI M et al: Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J Pharmacol Exp. Ther. (2003) 305:943–949.
   PubMed Web of Science ®Google Scholar
• IWASHITA A, MIHARA K, YAMAZAKI S etal.: A new poly(ADP-ribose) polymerase inhibitor, FR-261529 [2- (4-chloropheny9-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice. J. Pharmacol Exp. Ther. (2004) 310:1114–1124.
   Google Scholar